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useful for protecting oligodendrocytes in neuropathologies 
involving excitoxicity and ischemia/hypoxia.
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Introduction
Bruce Ransom has been at the forefront of white matter 
function in health and disease for many decades, for exam-
ple as reviewed by Ransom et  al. [1]. These early studies 
were amongst the first to demonstrate the importance of 
glutamate in mediating white matter damage and the pro-
tective effects of blocking ionotropic NMDA-type gluta-
mate receptors [2]. Bruce Ransom and colleagues made 
important advances using the optic nerve as an archetypal 
CNS white matter tract and oxygen-glucose deprivation as 
a model for ischemia, recently providing the first direct cor-
relation of excitoxic white matter injury in ischemia with 
glutamate release [3]. Moreover, Ransom and colleagues 
have provided evidence that CNS white matter is intrinsi-
cally more vulnerable to ischemic injury in older animals 
[4]. In addition to mediating axonal damage in white mat-
ter ischemia, glutamate acting via ionotropic AMPA- and 
NMDA-type glutamate receptors also causes damage to oli-
godendrocytes and myelin [5]. Indeed, glutamate-mediated 
excitoxicity and ischemia are features of multiple neuro-
pathologies, including periventricular leukomalacia (PVL), 
stroke, traumatic injury, multiple sclerosis and dementia 
[5–7]. Hence, it is important to understand cytodestructive 
and cytoprotective mechanisms in WM ischemia.
Notably, in addition to ionotropic glutamate receptors 
(iGluR), glial cells also express metabotropic glutamate 
Abstract Studies by Bruce Ransom and colleagues have 
made a major contribution to show that white matter is 
susceptible to ischemia/hypoxia. White matter contains 
axons and the glia that support them, notably myelinating 
oligodendrocytes, which are highly vulnerable to ischemic-
hypoxic damage. Previous studies have shown that metabo-
tropic GluRs (mGluRs) are cytoprotective for oligodendro-
cyte precursor cells and immature oligodendrocytes, but 
their potential role in adult white matter was unresolved. 
Here, we report that group 1 mGluR1/5 and group 2 
mGluR3 subunits are expressed in optic nerves from mice 
aged postnatal day (P)8–12 and P30–35. We demonstrate 
that activation of group 1 mGluR protects oligodendrocytes 
against oxygen-glucose deprivation (OGD) in developing 
and young adult optic nerves. In contrast, group 2 mGluR 
are shown to be protective for oligodendrocytes against 
OGD in postnatal but not young adult optic nerves. The 
cytoprotective effect of group 1 mGluR requires activation 
of PKC, whilst group 2 mGluR are dependent on negatively 
regulating adenylyl cyclase and cAMP. Our results identify 
a role for mGluR in limiting injury of oligodendrocytes in 
developing and young adult white matter, which may be 
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receptors (mGluR) widely throughout the brain [8]. 
mGluR are seven transmembrane domain G protein-cou-
pled receptors (GPCR) and are divided in three groups, 
based on their second messenger coupling, pharmacology 
and amino acid sequence [9]. Group I mGluRs (mGluR1 
and mGluR5) are positively coupled to phospholipase C 
(PLC) via Gαq/11 and inositol triphosphate  (IP3) forma-
tion, whilst group II (mGluR2 and mGluR3) and group 
III (mGluR4, mGluR6, mGluR7 and mGluR8) are neg-
atively coupled to adenylyl cyclase (AC) via  Gi/G0, 
and negatively regulate cAMP. Astrocytes prominently 
express group I mGluR1/5 that elicit a rise in  [Ca2+]i 
and can induce their release of glutamate and other neu-
rotransmitters, which can modulate synaptic responses 
[10, 11]. The role of mGluR in white matter is less 
well studied, but group I mGluR are protective against 
ischemia–hypoxia and glutamate-mediated excitotox-
ity in developing oligodendrocytes [12] and recently we 
provided evidence that mGluR5 protect astrocytes from 
ischemic damage in the mouse optic nerve [13]. In vitro, 
group 1 mGluR5 are highly expressed in oligodendro-
cyte precursor cells (OPCs) and are down-regulated as 
they differentiate into mature oligodendrocytes [12, 14]. 
In  vivo studies showed that group I mGluR1/mGluR5 
are expressed in immature oligodendrocytes of postnatal 
white matter and in human postmortem preterm tissue 
[15, 16], and group II mGluR3 appear to be expressed 
by OPCs and oligodendrocytes [14, 16]. It is not clear 
whether mGluR have a cytoprotective role in adult white 
matter, although as noted above there is considerable 
evidence that glutamate plays an enduring role in oligo-
dendrocytes and white matter pathology in the adult CNS 
[4, 6]. To address this, we have compared the effects of 
mGluR activation on oligodendrocytes in the develop-
ing and young adult mouse optic nerve, using the OGD 
model. Our results provide evidence of a persistent role 
for mGluR in limiting hypoxic–ischemic oligodendrocyte 
injury in postnatal and young adult white matter.
Materials and Methods
Animals
Mice aged postnatal day (P)8–12 and P30–35 were killed 
humanely, in accordance with the UK Animals (Scien-
tific Procedures) Act, 1986. Wild type (WT) mice of the 
C57BL/6 and transgenic mouse strains in which fluorescent 
reporters are driven by the oligodendroglial genes SOX10-
EGFP (gift from William Richardson, UCL, UK) or PLP-
DsRed (gift from Frank Kirchhoff, University of Saarland, 
Germany) were used throughout.
RT‑qPCR
WT mice aged P8–12 and P30–35 were humanely killed 
and optic nerves and cerebral cortex were rapidly removed. 
For cortices and postnatal optic nerves, homogenization 
was performed using a TissueRuptor (Qiagen, Hilden, Ger-
many). For the P30 optic nerve the abundance of myelin 
interferes with mRNA extraction and the homogenate was 
passed through a QIAshredder column (Qiagen), then 100 
µL chloroform (Sigma) was added and after centrifugation 
the top aqueous phase containing the RNA was transferred 
into an Eppendorf, where it was mixed at 1:1 ratio with 
70% ethanol. Subsequently, for all samples, RNA extrac-
tion was performed using the RNeasy Micro Kit (Qiagen), 
following the manufacturer’s instructions and total RNA 
samples were eluted in 10  µl RNA-free water. Genomic 
DNA was removed using DNase I (Qiagen) and RNA sam-
ples were stored at −80 °C prior to use. The purity and 
concentration of isolated total RNA was assessed using a 
ND-1000 Spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA), where a ratio of >1.8 indicated 
high RNA purity. The RT2 First Strand Kit (Qiagen) was 
used for in vitro transcription of extracted RNA into cDNA, 
following the manufacturer’s instructions. The quantity of 
RNA that was transcribed was the same for all samples 
(500 ng). For RT-qPCR, amplified cDNA was loaded with 
SYBR green mastermix and DNAase/RNAse free  H20 into 
a custom  RT2 Profiler™qPCR mGluR 96-well plate array 
(SABiosciences, Qiagen) for Lightcycler 96 (Roche Diag-
nostics). Relative gene expression was determined using 
the ΔΔCt method versus the housekeeping gene Glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH). Transcript 
expression data are presented as mean ± standard error of 
the mean (SEM), and samples compared for significance 
using ANOVA and post hoc Bonferroni’s tests in Prism 
v3.02 software (GraphPad).
Optic Nerve Explant Cultures 
and Immunocytochemistry
Optic nerve explant cultures were prepared from P8 PLP-
DsRed mice as previously described [17]. Briefly, optic 
nerves were placed directly into 50  µl dissecting medium 
consisting of high glucose Dulbecco’s Modified Eagle 
Medium (DMEM) (Sigma-D5671) containing 10% Fetal 
Calf Serum (FCS; Life Technologies), l-glutamine (Sigma) 
and 0.1% gentamycin (Life Technologies). Nerves were 
finely chopped with a scalpel blade and triturated with 
pipettes of decreasing diameter (P1000 then P200) to fur-
ther break up the tissue. After adding 50 µl more dissecting 
medium, the solution was pipetted evenly between poly-
l-lysine/laminin coated coverslips (approx. 1 nerve per 
cover-slip). After 24 h, the dissecting medium was replaced 
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with a low serum (0.5%) modified Bottenstein and Sato 
(B&S) culture medium [18], without thyroid hormones, in 
which 10 ng/ml of recombinant human PDGF-a (R&D Sys-
tems) was added to encourage OPC proliferation. After 3–4 
days in  vitro (DIV), the medium was replaced with B&S 
medium supplemented with 0.5 mM dbc-AMP (Sigma) to 
promote differentiation of oligodendrocytes, which were 
identified by their expression of the PLP-DsRed reporter. 
After 10 DIV, cultures were immersion fixed in 1% para-
formaldehyde (PFA) containing 15% picric acid for 10 min. 
Following washes in phosphate buffered saline (PBS), a 
blocking stage was performed by incubation in 10% nor-
mal goat (NGS) in PBS for 1–2 h, then washes in PBS and 
incubation overnight with primary antibodies in block-
ing solution containing 0.01% Triton-X-100: rabbit anti-
mGluR5, at 1:1000 (Neuromics); rabbit anti-mGluR2/3, at 
1:300 (Upstate). Samples were then washed 3 times in PBS 
and incubated with the appropriate secondary antibodies 
conjugated  with  488 Alexafluor. Following immunolabel-
ling, coverslips were mounted with Vectashield® (Vector-
Labs) and imaged using a Zeiss Axiovert LSM710 VIS405 
confocal microscope. Controls were performed in which 
coverslips were preabsorbed with antigen peptide overnight 
prior to incubation in the primary antibody for mGluR5 
and mGluR2/3, and no immunostaining was observed in 
these controls. Images were acquired using multichannel 
sequential scanning, narrow bandwidths, and minimal laser 
power and gain to prevent cross-talk between the channels; 
a pinhole of 1 airy unit or less was used, with an average of 
4 scans per image.
Oxygen–Glucose Deprivation
Optic nerves from P8–12 or P30–35 transgenic PLP-DsRed 
or Sox10-EGFP mice were isolated intact and immediately 
placed in oxygenated aCSF at 37 °C for 30 min, compris-
ing (in mM): NaCl,133; KCl, 3;  CaCl2, 1.5;  NaH2PO4, 1.2; 
 MgCl2, 1.0; d-glucose. 10; HEPES, 10; pH 7.3. Controls 
were incubated for a further 1 h in normal aCSF contain-
ing 10  mM glucose with 95%  O2/5%  CO2. Oxygen–glu-
cose deprivation (OGD) was achieved using the method 
of Fern and colleagues [19], by incubating nerves for 1 
h at 37 °C in glucose-free aCSF (osmolarity was main-
tained by replacing glucose with sucrose), and switch-
ing the chamber atmosphere to 95%N2/5%CO2. The use 
of 10 mM HEPES buffer ensured the pH remained steady 
throughout these short experiments and the control data 
demonstrates that oligodendrocytes remain viable in these 
conditions. Pharmacological agents were added directly 
to the aCSF solution (purchased from Tocris and used at 
100 µM unless otherwise stated): group I/II mGluR ago-
nist ACPD [(±)-1-Aminocyclopentane-trans-1,3-dicar-
boxylic acid]; selective group I mGluR agonist DHPG 
[(RS)-3,5-Dihydroxyphenylglycine]; highly selective group 
II mGluR agonist LY379268 ((1R,4R,5S,6R)-4-amino-2-ox-
abicyclo[3.1.0]hexane-4,6-dicarboxylic acid); potent pro-
tein kinase C (PKC) inhibitor (10µM) Go6976 (5,6,7,13-tet-
rahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4-c]
carbazole-12-propanenitrile); membrane permeable cAMP 
analogue dbcAMP  (N6,2′-O-dibutyryladenosine 3′,5′-cyclic 
monophosphate sodium salt, Sigma); membrane perme-
able activator of adenylyl cyclase forskolin ([3R-(3α,4aβ,5-
β,6β,6aα,10α,10aβ,10bα)]-5-(acetyloxy)-3-ethenyldodec
ahydro-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1
H-naphtho[2,1-b]pyran-1-one, Sigma). At the end of the 
experiments, nerves were rapidly fixed for 1 h in 4% PFA 
and whole-mounted with vectashield. Cell counts were 
performed in whole mounts of fixed optic nerve, using a 
constant volume of 20 × 20 µm in the x-y-plane and 15 µm 
in the z-plane, captured using a Zeiss LSM 710 Metaconfo-
cal microscope, as previously described [20]. Images were 
captured at the midway along the length of the optic nerve, 
to avoid the cut ends, and at a depth of 15 µm beneath the 
pial surface. Expression of the transgenic marker EGFP or 
DsRed identifies viable cells and a decrease in their num-
ber reflects the number of cells that died, ruptured and dis-
appeared over the 60 min experimental period. Cell death 
was also measured in WT mice using propidium iodide 
(PI, 1  μg/μl; Sigma), which is membrane impermeant in 
viable cells, from which PI is excluded, and only perme-
ates the membranes of cells that are unviable and will sub-
sequently die; PI staining and EGFP/DsRED imaging was 
not performed in the same cells. Data were expressed as 
mean ± SEM, where each ‘n’ value represents a separate 
nerve, and significance was determined by ANOVA and 
Newman-Keuls multiple comparison post-hoc analysis, 
using Prism 5.0 (Graphpad).
Results
mGluR in the Postnatal and Young Adult Mouse Optic 
Nerve
RT-qPCR was used to analyse expression of group I mGluR 
(mGluR1 and mGluR5) and group II mGluR (mGluR2 and 
mGluR3) subtypes in the optic nerve, compared to the cor-
tex, from developing (P8–12) and young adult (P30–35) 
WT mice, using a custom  RT2 Profiler™qPCR array (Sabi-
osciences, Qiagen). In the cortex, transcripts for all sub-
types were detected, mGluR1 (Grm1), mGluR3 (Grm3) 
and mGluR5 (Grm5) being most abundant, and there were 
no significant differences between developing and young 
adult (Fig.  1, inset). In contrast, mRNA for mGluR2 was 
barely detectable at either age in the optic nerve, whereas 
mGluR1, mGluR3 and mGluR5 were detected and were 
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significantly upregulated between P12 and P30, to levels 
observed in the cortex (Fig. 1; ANOVA and post hoc Bon-
ferroni’s tests, p < 0.001). The optic nerve does not contain 
neuronal cell bodies and >95% of mRNA is oligodendro-
glial and astroglial [19]. The RT-qPCR results indicate 
a developmental increase in glial mGluR1, mGluR5 and 
mGluR3. Immunolabelling in optic nerve explant cultures 
prepared from P8 PLP-DsRed reporter mice confirms 
that after 10 DIV PLP-DsRed + oligodendrocytes express 
mGluR5 and mGluR3 (Fig.  1b, c); immunostaining for 
mGluR5 was greater than for mGluR2/3 and the former 
appears to be strong in the cell body, which is consistent 
with the literature [12, 15].
mGluR Protect Oligodendrocytes from Ischemia–
Hypoxia In Situ in the Postnatal Optic Nerve
Immature oligodendrocytes and OPCs are highly sensi-
tive to glutamate-mediated ischemia–hypoxia [6, 21] 
and mGluR have been shown to protect OPCs from 
glutamate-mediated excitotoxicity in  vitro [12, 22]. 
The expression of both group I and group II mGluR in 
Fig. 1  Expression of mGluR in optic nerve oligodendrocytes. a RT-
qPCR of mGluR subtypes in the postnatal (P8–12) and young adult 
(P30–35) optic nerve, compared to cortex at the same ages (inset); 
data are expressed as mean ± SEM ΔΔCT relative to GAPDH, 
***p < 0.001 determined by ANOVA and post hoc Bonferroni’s 
test. b, c Oligodendrocytes in optic nerve explant cultures from P8 
PLP-DsRed reporter mice after 10 DIV were immunolabelled for 
mGluR2/3 (d) and mGluR5 (e), illustrating single channels (Di, Dii, 
Ei, Eii) and the merged channel in which mGluR colocalization with 
PLP appears white (Diii, Eiii); scale bars 10 µm
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PLP + oligodendrocytes shown above suggested they may 
have a protective role in oligodendrocytes as well as OPCs. 
Hence, we examined the effects of mGluR activation on 
oligodendrocytes in situ in the isolated intact mouse optic 
nerve from mice aged P8–12 (Fig. 2). First, to examine cell 
death, we used PI labelling in WT nerves; PI is membrane 
impermeant and excluded from viable cells, and only per-
meates the membranes of cells that are unviable and will 
subsequently die. Optic nerves were incubated for 60 min 
in normoxic or OGD conditions in normal aCSF + PI or 
aCSF + PI containing ACPD (Fig.  2a, b, d insets); at the 
end of the experiments, nerves were rapidly immersion 
fixed and whole-mounted for examination using a confocal 
microscope to identify PI labeled dying cells (many cells 
that died earlier will have lysed and disappeared). Com-
pared to acutely dissected nerves, there was no significant 
cell death following incubation in normoxic aCSF for 1 h, 
whereas OGD resulted in significant cell death (p < 0.05), 
compared to normoxic controls, and this was completed 
blocked by incubation in the general mGluR agonist ACPD, 
Fig. 2  mGluR activation protects postnatal optic nerve oligoden-
drocytes from OGD. a, b Representative confocal images of whole-
mounted optic nerves from P8 SOX10-EGFP mice (a) and PLP-
DsRed mice (b) that were exposed to OGD for 1 h, in the presence 
or absence of the group I/II agonist ACPD, specific group I agonist 
DHPG, or group II agonist LY379268 (all 100  µM), compared to 
control nerves incubated in normal aCSF with  O2 + glucose; scale 
bar 50  µm. c, d Quantification of the number of SOX10-EGFP+ 
cells (c) and PLP-DsRed + cells (d), in constant fields of view (FOV) 
(mean ± SEM, n = 6 nerves per experimental group; ***p < 0.001, 
ANOVA with Newman–Keuls multiple comparison post-hoc analy-
sis). Insets in a are representative images of PI labeling used to meas-
ure cell death and quantification of the number of  PI+ cells is illus-
trated in the inset in d
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which activates both group I and group II mGluR (insets in 
Fig. 1a, b, d). These results demonstrate that nerves remain 
viable in the absence of OGD, as previously reported using 
the same techniques [19, 20], and supports evidence that 
mGluR are cytoprotective against OGD in white matter 
in vivo [15].
To dissect the roles of group I and II mGluR on oligo-
dendrocytes and OPCs specifically, we used transgenic 
Sox10-EGFP and PLP-DsRed reporter mice (Fig. 2). Sox10 
is expressed throughout the oligodendrocyte lineage [23], 
hence Sox10-EGFP identifies both oligodendrocytes and 
OPCs (Fig.  2a, c), whereas PLP-DsRed identifies mainly 
oligodendrocytes (Fig. 2b, d) [24]. Optic nerves were incu-
bated for 60  min in normoxic or OGD conditions in nor-
mal aCSF or aCSF containing one of the mGluR antago-
nists (Fig. 2) and at the end of the experiments, nerves were 
rapidly immersion fixed. Nerves were whole-mounted for 
examination using a confocal microscope and cell counts 
were performed in each nerve in a constant FOV, compris-
ing 20 × 20 × 15 µm in the x-y-z plane, at a point midway 
along the length of the optic nerve and 15 µm beneath the 
pial surface, as previously described [20]. Expression of the 
transgenic marker EGFP or DsRed identifies viable cells 
and a decrease in their number reflects the number of cells 
that have died, ruptured and consequently disappeared over 
the 60  min experimental period; this avoided the issues 
of live cell imaging, where tissue swelling and movement 
results in some cells moving in or out of the confocal plane, 
while other cells may fade without dying. Compared to 
normoxic controls, OGD resulted in a significant decrease 
in oligodendrocytes, in the SOX10-EGFP nerves (Fig. 2a, 
c, p < 0.001) and PLP-DsRed nerves (Fig. 2b, d, p < 0.001). 
Incubation with ACPD, the specific group I agonist DHPG, 
or group II agonist LY379268 both had a significant cyto-
protective effect against OGD in Sox10-EGFP + oligoden-
drocytes (Fig.  2a, c, p < 0.001) and PLP-DsRed + oligo-
dendrocytes (Fig.  2b, d, p < 0.001). The total number of 
oligodendrocytes that died during the 60 min experimental 
period is measured by the decrease in the total number of 
cells expressing the transgenic markers (Fig. 2c, d) and is 
greater than the number of PI stained cells per FOV at the 
end of the experiment (Fig. 2d, inset), which is a measure 
of the number cells undergoing cell death at that time. The 
results indicate mGluR have a cytoprotective effect on oli-
godendrocytes in the postnatal optic nerve, in support of 
in vitro studies [12, 22].
Group I mGlu, Protect Oligodendrocytes 
from Ischemia–Hypoxia in Young Adult Optic Nerve
Mature oligodendrocytes are susceptible to glutamate-
mediated excitotoxcity in adult white matter pathology, 
including ischemia–hypoxia and multiple sclerosis [6, 7], 
and increased expression of group I and group II mGluR 
suggests their cytoprotective role may persist in the adult 
optic nerve. Hence, we examined the effects of mGluR 
activation on oligodendrocytes in situ in the isolated intact 
mouse optic nerve from mice aged P33 (Fig. 3). After 1 h 
OGD in the young adult nerve, there was a significant 30% 
loss of PLP1-DsRed+ oligodendrocytes compared to nor-
moxic controls (Fig.  2a, b, e, p < 0.001). Incubation with 
the group I mGluR agonist DHPG significantly protected 
oligodendrocytes from OGD (Fig.  3b, c, e, p < 0.05), and 
there was no significant difference between OGD + DHPG 
and normoxic controls (Fig. 3a, c, e, p > 0.05). In contrast, 
the group II mGluR agonist LY379268 did not protect 
against OGD (Fig.  3d, e); there was no significant differ-
ence between OGD and OGD + LY379268 (Fig.  3b, d, e, 
p > 0.05), and the number of oligodendrocytes was signifi-
cantly less than in OGD + DHPG and normoxic controls 
(Fig. 3a, d, e, p < 0.01). The results demonstrate that group 
I mGluR are cytoprotective against ischemia–hypoxia in 
oligodendrocytes in the young adult optic nerve in situ, but 
the cytoprotective effects of group II mGluR declines with 
development.
The Protective Effect of Group I mGluR 
on Oligodendrocytes is Mediated by PKC
Group I mGluR act via phosholipase C (PLC) and an 
 IP3-dependent increase of intracellular  Ca2+ to activate 
protein kinase C (PKC), which mediates the protec-
tive effect of mGluR in hypoxic-ischemic injury in OPCs 
in  vitro [12]. To examine this in oligodendrocytes, the 
PKC inhibitor Go6976 (10  µM) was used in conjunction 
with the group I mGluR agonist DHPG, in optic nerves 
from P11 PLP1-DsRed reporter mice (Fig.  4). The cyto-
protective effect of DHPG was completely abolished by 
Go6976, with the number of PLP + oligodendrocytes in 
OGD + DHPG + Go6976 being not significantly differ-
ent than in OGD alone (Fig. 4b, d, p < 0.001), and signifi-
cantly less than in OGD + DHPG (Fig. 4c, d, e, p < 0.001), 
or normoxic controls (Fig. 4a, d, e, p < 0.001). The results 
demonstrate that group I mGluR mediate their pro-survival 
effect on PLP + oligodendrocytes via PKC activation.
The Protective Effect of Group II mGluR on Immature 
Oligodendrocytes is Dependent on cAMP
The results presented above demonstrated that group II 
mGluR protect immature oligodendrocytes against OGD in 
postnatal nerves. Since mGluR2 were barely detectable in 
the postnatal nerve, these effects are most likely mediated 
by mGluR3, which have an established cytoprotective role 
in neurons and astrocytes by inhibition of adenylyl cyclase 
(AC) and reduction of cAMP levels [25, 26]. We examined 
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this in optic nerves from P11 PLP-DsRed mice, using the 
membrane permeable cAMP analogue dbcAMP (100 µM) 
to exogenously raise intracellular cAMP and the AC acti-
vator forskolin (100  µM) to raise endogenous cAMP. 
Both dbcAMP and forskolin counteracted the cytoprotec-
tive actions of group II mGluR activation in oligodendro-
cytes (Fig.  5). Incubation with dbcAMP had no effect on 
OGD-mediated oligodendrocyte loss, but the number of 
PLP-DsRed + oligodendrocytes was significantly less in 
OGD + dbcAMP + LY379268 than in OGD + LY379268 
(p < 0.001), or normoxic controls (p < 0.01) (Fig.  5a, b). 
Fig. 3  mGluR activation protects oligodendrocytes in young adult 
optic nerves from OGD. Optic nerves from P33 PLP1-DsRed reporter 
mice were exposed to 1 h OGD in the presence or absence of the spe-
cific group I agonist DHPG or group II agonist LY379268 (both at 
100 µM), compared to control nerves incubated in normal aCSF with 
 O2 + glucose. a–d Representative images of PLP1-DsRed+ oligoden-
drocytes in isolated intact optic nerves incubated in  O2 (a), OGD (b), 
OGD + DHPG (c), or OGD + LY (d); scale bars 50 µm. e Quantifica-
tion of the number of PLP1-DsRed + cells in constant fields of view 
(FOV) (mean ± SEM, n = 6 nerves per experimental group; *p < 0.05, 
**p < 0.01, ***p < 0.001, ANOVA with Newman–Keuls multiple 
comparison post-hoc analysis)
Fig. 4  Protective effect of group I mGluR in oligodendrocytes 
depends on PKC activation. Optic nerves from P11 PLP1-DRed 
reporter mice were exposed to 1  h OGD in the presence of the 
group I mGluR agonist DHPG (100 µM) and presence or absence 
of the PKC inhibitor Go6976 (10 µM), compared to normoxic con-
trols incubated in normal aCSF with  O2 + glucose. a–d Representa-
tive images of PLP1-DsRed+ oligodendrocytes in isolated intact 
optic nerves incubated in  O2 (a), OGD (b), OGD + DHPG (c), or 
OGD + DHPG + Go6976 (d); scale bars = 50 µm. e Quantification of 
the number of PLP1-DsRed + cells in constant fields of view (FOV) 
(mean ± SEM, n = 5 nerves per experimental group; ***p < 0.001, 
ANOVA with Newman–Keuls multiple comparison post-hoc analy-
sis)
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Similarly, incubation in forskolin, to activate AC and raise 
endogenous cAMP, had no effect on oligodendrocyte loss 
in OGD, but the number of PLP-DsRed + oligodendrocytes 
was significantly less in OGD + forskolin + LY379268 
than in OGD + LY379268 (p < 0.05), or normoxic controls 
(p < 0.001) (Fig.  5a, c). The results demonstrate that the 
cytoprotective effect of group II mGluR on oligodendro-
cytes is dependent on a decrease in cAMP, which can be 
reversed by pharmacologically raising cytoplasmic cAMP.
Discussion
Oligodendrocytes are highly susceptible to glutamate-
mediated excitoxicity in the developing and adult brain 
[6]. Here, we show that mGluR protect oligodendrocytes 
from ischemic-hypoxic injury in situ in the optic nerve of 
postnatal and young adult mice. Group I and II mGluR 
are developmentally upregulated in the mouse optic nerve, 
indicating an enduring role for mGluR in glial glutamate 
signaling, which is a prominent feature of white matter [7]. 
Group I mGluR are cytoprotective for oligodendrocytes 
at all stages of differentiation and development, whereas 
the cytoprotective effect of group II mGluR was lost in 
the P30 nerve. The results suggest that targeting specific 
mGluRs at different developmental ages could contribute 
to strategies for protecting immature and mature oligoden-
drocytes in neuropathologies involving excitoxicity and 
ischemia–hypoxia.
In vivo expression of mGluR in the optic nerve was con-
firmed by RT-qPCR, which identified mRNA for mGluR1, 
mGluR3 and mGluR5 in the postnatal optic nerve, and 
Fig. 5  Protective effect of group II mGluR in oligodendrocytes 
depends on inhibition of adenylyl cyclase and reduced intracel-
lular cAMP. Optic nerves from P11 PLP1-DsRed reporter mice 
were exposed to 1  h OGD in the presence or absence of the group 
II mGluR agonist LY379268 (100  µM), together with the mem-
brane permeable cAMP analogue dbcAMP (100  µM) or forsko-
lin (100  µM) to activate adenylyl cyclase and raise endogenous 
cAMP. a Representative images of PLP1-DsRed+ oligodendrocytes 
in isolated intact optic nerves in normoxic controls  (O2 + Glu-
sose), OGD, OGD + LY379268, OGD + LY379268 + dbcAMP and 
OGD + LY379268OGD + forskolin; scale bar 50 µm. b, c Quantifica-
tion of the number of PLP1-DsRed + cells in constant fields of view 
(FOV) to determine the effects of dbcAMP (b) and forskolin (c) on 
the protective effects of LY379268 (mean ± SEM, n = 5 nerves per 
experimental group; *p < 0.05, **p < 0.01, ***p < 0.001, ANOVA 
with Newman–Keuls multiple comparison post-hoc analysis)
2476 Neurochem Res (2017) 42:2468–2478
1 3
these were markedly upregulated at P30, to levels observed 
in the cortex. The bulk of mRNA in the optic nerve is from 
oligodendrocytes and astrocytes [19], and our previous 
studies have demonstrated functional mGluR in optic nerve 
glia [27]. Our results support evidence that oligodendro-
cytes express group I mGluR1/mGluR5 in postnatal rodent 
white matter and in human postmortem preterm tissue [15, 
16], and our finding that group II mGluR3 are expressed by 
PLP + oligodendrocytes from postnatal nerves is consistent 
with in vitro studies [14, 16].
In the postnatal optic nerve, OGD-resulted in a 70% loss 
of PLP + oligodendrocytes compared to 30% in the P30 
nerve. The postnatal mouse optic nerve correlates devel-
opmentally to human fetal white matter that is highly sus-
ceptible to ischemia–hypoxia, resulting in hypomyelination 
in periventricular leukomalacia (PVL) and cerebral palsy 
[28]. Our results support evidence that immature oligoden-
drocytes are more vulnerable than mature oligodendrocytes 
to ischemia–hypoxia [29], but also support evidence that 
CNS white matter is vulnerable to ischemic injury in older 
animals [4]. Interestingly, a key aspect of glial and axonal 
demise in ischemic white matter is the massive release of 
glutamate into the extracellular space [3]. The cytodestruc-
tive effects of glutamate in oligodendrocytes and myelin are 
mediated by AMPA- and NMDA-type iGluR and blockade 
of NMDA receptors is protective for oligodendrocytes and 
axonal integrity [2, 5, 19, 30, 31]. Our results indicate that 
mGluR serve to potentially protect oligodendrocytes, but 
the loss of oligodendrocytes in ischemia–hypoxia indicates 
that without pharmacological intervention the cytodestruc-
tive effects of iGluR outweigh the cytoprotective effects of 
mGluR.
Group I and II mGluR were both protective for oligo-
dendrocytes in the postnatal optic nerve, whereas only 
group I were protective in young adults, and were less 
effective than in postnatal nerves. The cytoprotective effect 
mediated by group I mGluR requires activation of PKC, 
which has also been shown in vitro in OPCs subjected to 
kainate exposure and OGD [12]. The protective effects of 
group II mGluR in immature oligodendrocytes support 
studies showing LY379268 is neuroprotective in ischemia 
[25]. The protective effect of LY379268 in the optic nerve 
is most likely mediated by mGluR3, since mGluR2 were 
barely detectable, and is dependent on inhibition of adeny-
lyl cyclase and reduced cAMP levels, which in astrocytes 
has been shown to result in activation of the prosurvival 
PI3K/Akt pathway [26].
Ischemia–hypoxia causes depolarization of oligodendro-
cytes and a consequent rise in  [Na+]i, which result in rever-
sal of the  Na+–Ca2+-exchanger (NCX) and  Ca2+ influx, 
triggering apoptosis [32, 33]. Notably, activation of group 
I mGluR has been reported to activate NCX in neurons 
[34, 35], which may be involved in the protective effects 
of mGluR5 in the optic nerve. Another important factor in 
ischemia–hypoxia is decreased astroglial glutamate uptake, 
which results in raised extracellular glutamate and is a 
major cause of oligodendrocyte loss in OGD [6]. mGluR5 
are cytoprotective for astrocytes [13, 36] and stimulate 
astroglial glutamate uptake [37], which could have indirect 
protective effects on oligodendrocytes by attenuating the 
loss of astroglial homeostatic functions in the optic nerve. 
Furthermore, mGluR can stimulate release of brain derived 
neurotrophic factor (BDNF) from astrocytes, which is neu-
roprotective and decreases myelin loss following demyeli-
nation [38]. mGluR also increase BDNF release from oli-
godendrocytes, through a PLC pathway [39]. In addition, 
group I mGluR inhibit microglial production of NO and 
reactive oxygen species, which are cytotoxic for oligoden-
drocytes [40]. It is likely that mGluR activation activates 
multiple mechanisms in the optic nerve that are cytoprotec-
tive for oligodendrocytes.
The results provide novel evidence that group I 
and group II mGluR protect oligodendrocytes from 
ischemia–hypoxia. The apparent developmental decrease 
in the efficacy of mGluR-mediated cytoprotection contrasts 
with the marked upregulation of mGluR1/5 and mGluR3 in 
the adult optic nerve, suggesting an important unresolved 
function for mGluR in adult white matter. Overall, this 
study indicates that mGluR represent a potential therapeu-
tic strategy to protect oligodendrocytes in pathologies that 
involve hypoxia–ischemia and excitoxicity, which is rel-
evant to stroke, PVL and cerebral palsy, multiple sclerosis, 
neurodegenerative diseases and dementia.
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